Tag Archives: Olivier Charmeil

Sanofi to add Rezurock™ to its transplant portfolio with the acquisition of Kadmon Holdings, Inc.

Adds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy (PRESS RELEASE) PARIS, 8-Sep-2021 — /EuropaWire/ — Sanofi … Read the full press release

Sanofi Pasteur starts phase III clinical trial in India for its investigational rotavirus vaccine manufactured by its affiliate Shantha Biotechnics in Hyderabad, India

The live, oral, ready-to-use tetravalent rotavirus vaccine candidate is designed to protect young children from severe diarrhea Lyon, France, 15-10-2014 — /EuropaWire/ — Sanofi Pasteur, the vaccines division of Sanofi, announced today the start of a phase III clinical trial in India … Read the full press release

Sanofi Pasteur announced its pediatric pentavalent vaccine Shan5™ received prequalification status from the World Health Organization

Shan5™ is the first vaccine jointly developed by the Indian company and its parent company Sanofi Pasteur  WHO’s decision allows for the purchase of Shan5™ by United Nations agencies Lyon, France, 7-5-2014 — /EuropaWire/ — Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: … Read the full press release